Endo Pushes FDA for Stricter Generic Opana Requirements
Endo Pharmaceuticals is petitioning the FDA to require that generic-makers referencing its crush-resistant pain drug Opana ER CRF demonstrate their products are similarly crush-resistant.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.